Assembly Biosciences Inc. (NASDAQ: ASMB) announced the completion of its underwritten public offering, raising approximately $115 million in gross proceeds before fees and expenses.

The biotechnology company sold 3,924,624 shares of common stock at $26.50 per share. The offering included the full exercise of underwriters' option to purchase an additional 566,040 shares. Assembly Biosciences also issued pre-funded warrants to an existing investor for 415,000 shares at $26.499 per warrant, representing the share price minus a $0.001 exercise price.

The company stated it plans to use net proceeds to fund clinical development of pipeline candidates and general corporate purposes. Assembly Biosciences develops therapeutics targeting viral and liver diseases including herpesvirus, hepatitis delta virus, cholestatic liver diseases and hepatitis B virus.

Guggenheim Securities and UBS Investment Bank served as joint book-running managers for the offering. Mizuho acted as a book-running manager and H.C. Wainwright & Co. served as lead manager.

The securities were sold under a shelf registration statement that became effective March 27, 2026. The offering documents are available through the Securities and Exchange Commission website and the underwriters.

Assembly Biosciences is based in South San Francisco and focuses on developing small-molecule therapeutics for serious viral and liver diseases.